Following a positive Q4 2018 preliminary revenue announcement days before their JPM 2019
presentation ($69.6m Q4, $248m for 2018), Novocure (NVCR) began with a review regarding
Optune’s adoption in 2018. The company emphasized a more than 40% growth in prescriptions
for newly diagnosed glioblastoma, a promising collaboration with Zai Lab to accelerate clinical
trial enrollment in China, and approval for national reimbursement in Sweden, which the
company views as a positive signal for reimbursement in other European markets. The company
also submitted a HDE application to the FDA for unresectable malignant pleural mesothelioma in
2018 and is optimistic about an approval and launch in the US in 2019. Leading up to 2022, the
company expects readouts for Optune in several indications, including for the HEPANOVA trial in
liver cancer, the LUNAR trial for non-small cell lung cancer (NSCLC), the METIS trial for brain
metastases arising from NSCLC, the PANOVA-3 in pancreatic cancer, and the INNOVATE-3 trial in
ovarian cancer.
presentation ($69.6m Q4, $248m for 2018), Novocure (NVCR) began with a review regarding
Optune’s adoption in 2018. The company emphasized a more than 40% growth in prescriptions
for newly diagnosed glioblastoma, a promising collaboration with Zai Lab to accelerate clinical
trial enrollment in China, and approval for national reimbursement in Sweden, which the
company views as a positive signal for reimbursement in other European markets. The company
also submitted a HDE application to the FDA for unresectable malignant pleural mesothelioma in
2018 and is optimistic about an approval and launch in the US in 2019. Leading up to 2022, the
company expects readouts for Optune in several indications, including for the HEPANOVA trial in
liver cancer, the LUNAR trial for non-small cell lung cancer (NSCLC), the METIS trial for brain
metastases arising from NSCLC, the PANOVA-3 in pancreatic cancer, and the INNOVATE-3 trial in
ovarian cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.